Login to Your Account

Actelion seeks CFDA approval for Zavesca in ultra-rare Niemann-Pick Type C

By Cornelia Zou
Staff Writer

Wednesday, January 8, 2014

HONG KONG – Swiss biopharmaceutical Actelion Ltd. is seeking regulatory approval in China for its Zavesca (miglustat) to treat Niemann-Pick Type C (NPC), a rare disease for which there is little information and no treatment available in the country.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription